Provider Profile:
Craig Cole, M.D.

School

• The Ohio State University College of Medicine

Residency

• University of Michigan Hospitals

Fellowships

• University of Michigan Hospitals

Awards

• ABPAFS of the University of Michigan Award for Outstanding Performance and Leadership, University of Michigan
• Gila’s Club/ Cancer Support Community Signature Program Support Award
• Multiple Myeloma Research Foundation Collaborator Award
• Top Blacks in Healthcare Award Recipient
• BlackDoctor.org and The George Washington University Milken Institute School of Public Health

Professional Memberships

• American Society of Hematology
• International Myeloma Working Group
• International Myeloma Society

• Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D, Anderson KC. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem, 2003 Feb 21; 278(8):5794-5801.
• Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, BazR, Nooka A, Richter J, Cole CE, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, VanWier S, Ahmann G, Ilsel Lopez I, KauffmanM, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-JuliakC, and Stewart AK. Selective Inhibition of Nuclear ExportWith Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol, 2018. Mar 20;36(9):859-866
• Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole CE, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 Aug 22;381(8):727-738.
• Dimopoulos M, Bringhen S, Anttila P, Capra M, Cavo M, Cole C, Gasparetto C, Hungria V, Jenner M, Vorobyev V, Ruiz EY, Yin JY, Saleem R, Hellet M, Macé S, Paiva B, Vij R. Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2021 Mar 4;137(9):1154-1165.
• Vo JN, Wu YM, Mishler J, Hall S, Mannan R, Wang L, Ning Y, Zhou J, Hopkins AC, Estill JC, Chan WKB, Yesil J, Cao X, Rao A, Tsodikov A, Talpaz M, Cole CE, Ye JC; Multiple Myeloma Research Consortium, Bergsagel PL, Auclair D, Cho HJ, Robinson DR, Chinnaiyan AM. The Genetic Heterogeneity And Drug Resistance Mechanisms Of Relapsed Refractory Multiple Myeloma. Nat Commun. 2022 Jun 29;13(1):3750. doi: 10.1038/s41467-022-31430-0. PMID: 35768438.